Diagnosis and treatment of cytomegalovirus infection

Current Opinion in Hematology

Volumn 5, Issue 6, 1998, Pages 483-487

  Hebart, Holger ^b   Einsele, Hermann ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LOBUCAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALACICLOVIR;

ARTICLE; ASSAY; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CYTOMEGALIC INCLUSION BODY DISEASE; DIAGNOSTIC PROCEDURE; HUMAN; NEPHROTOXICITY; NEUTROPENIA; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VIRUS IMMUNITY; VIRUS LOAD;

EID: 0031797881     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199811000-00022     Document Type: Article

References (41)

1. Aversa F, Martelli MM, Reisner Y: Use of stem cells from mismatched related donors. Curr Opin Hematol 1997, 4:419-422.
2. Link H, Arseniev L, Ljungman P, et al.: Cytomegalovirus infections after allogeneic peripheral blood progenitor cell transplantation (PBPCT): a survey of the infectious diseases working party of EBMT [abstract 479]. Bone Marrow Transplant 1998, 21(suppl 1):139.
3. Hebart H, Brugger W, Klingebiel T, Sinzger G, Jahn G, Müller CA, et al.: CMV infection following transplantation of allogeneic peripheral blood progenitor cells from related donors [abstract 484]. Bone Marrow Transplant 1998, 21(suppl 1):139.
4. Limaye AP, Bowden RA, Myerson D, Boeckh M: Cytomegalovirus disease occurring before engraftment in marrow transplant recipients. Clin Infect Dis 1997, 24:830-835.
5. Boeckh M, Riddell SR, Cunningham T, Myerson D, Flowers M, Bowden RA: Increased risk of late CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T-cell responses [abstract 1195]. Blood 1996, 88(suppl 1):643.
6. Einsele H, Hebart H, Kauffman C, Sinzger C. Jahn G, Klingebiel T, et al.: Late onset CMV disease after allogeneic stem cell transplantation [abstract 0337]. Bone Marrow Transplant 1997, 19(suppl 1):85.
7. Söderberg-Naucler C, Fish KN, Nelson JA: Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997, 91:119-126. The authors were the first to demonstrate reactivation of cytomegalovirus (CMV) in long-term cultures of allogeneically stimulated adherent monocyte-derived macrophages. The cells harboring reactivated virus were found to be CD14 and CD83 positive, thus providing the first evidence that myeloid lineage cells in the peripheral blood of healthy individuals are the source of latent CMV.
8. Söderberg-Naucler C, Fish KN, Nelson JA: Interferon-γ and Tumor Necrosis Factor-α specifically induce formation of cytomegalovirus-specific monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest 1997, 100:3154-3163.
9. + peripheral blood mononuclear cells from CMV-infected individuals. Transplantation 1998, 65:411-415.
10. Hahn G, Jores R, Mocarski ES: Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A 1998, 3937-3942. The authors suggest that early hematopoeitic progenitor cells express latency-associated transcripts and proteins upon differentiation into lineage-committed progenitors.
11. H2-type cytokines and lack of T-cell mediated cytotoxicity. Transplantation 1997, 63:1782-1789.
12. Mori T, Ando K, Tanaka K, Ikeda Y, Koga Y: Fas-mediated apoptosis of the hematopoietic progenitor cells in mice infected with murine cytomegalovirus. Blood 1997, 89:3565-3573.
13. Torok-Storb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T: Association of specific CMV genotypes with death from myelosuppression after marrow transplantation. Blood 1997, 90:2097-2102. A retrospective analysis, describing the association of particular cytomegalovirus genotypes with death due to myelosuppression in marrow transplant recipients.
14. Krause H, Hebart H, Jahn G, Müller CA, Einsele H: Screening for CMV-specific T cell proliferation to identify patients at risk to develop late onset CMV disease. Bone Marrow Transplant 1997, 19:1111-1116.
15. Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H: Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral stem cell or bone marrow transplants. Blood 1997, 89:3873-3879. The authors demonstrate a markedly shortened recovery of the cytomegalovirus (CMV) directed immune responses after autografting compared with allografting, explaining the much lower incidence of CMV disease after autologous transplants.
16. Yee C, Riddell SR, Greenberg PD: Prospects for adoptive T cell therapy. Curr Opin Immunol 1997, 9:702-709.
17. Diamond DJ, York Y, Sun J-Y, Wright CL, Forman SJ: Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997, 90:1751-1767. The authors demonstrate vaccine function of a pp65 nonamer peptide without adjuvant, suggesting the potential for use of this peptide in imunization trials.
18. Steffens HP, Kurz S, Holtappels R, Reddehase MJ: Preemptive CD8+ -cell immunotherapy of acute CMV infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol 1998, 72:1797-1804. The authors demonstrate antiviral CD8+ cells to prevent cytomegalovirus (CMV) disease, to accelerate resolution of productive CMV infection, and to result in a lower load of latent CMV DNA in organs, as compared with results in control animals. However, antiviral CD8+ cells were not able to completely eliminate CMV.
19. Roegh HL: Viral strategies of immune evasion. Science 1998, 280:248-253. Summary of the major mechanisms used by viruses to subvert normal host defenses.
20. Miller DM, Rahill BM, Boss JM, Lairmore MD, Durbin JE, Waldman WJ, Sedmak DD: Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med 1998, 187:675-683. The authors demonstrate CMV-mediated inhibition of MHC class II expression via compromise of the JAK/STAT pathway.
21. Hebart H, Schroeder A, Loeffler J, Klingebiel T, Martin H, Wassmann B, et al.:CMV-monitoring by PCR of patients undergoing autologous bone marrow and peripheral blood progenitor cell transplantation. J Infect Dis 1997, 172:939-943.
22. Gor D, Sabin D, Prentice HG, Vyas N, Man S, Griffith PD, Emery VC: Longitudinal analysis in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, GvHD and disease. Bone Marrow Transplant 1998, 21:597-605.
23. Zaia JA, Gallez-Hawkins GM, Tegtmeier BR, ter Veer A, Li X, Niland JC, Forman SJ: Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997, 176:782-785.
24. Hebart H, Gamer D, Loeffler J, Mueller CA, Sinzger C, Jahn G, et al.: Evaluation of the Murex CMV DNA hybrid capture assay for detection and quantitation of cytomegalovirus infection in patients following allogeneic stem cell transplantation. J Clin Microbiol 1998, 36:1333-1337.
25. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA: Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation. Transplantation 1997, 64:108-113.
26. Hiyoshi M, Tagawa S, Takubo T, Tanaka K, Nakao T, Higeno Y, et al.: Evaluation of AMPLICOR CMV test for direct detection of cytomegalovirus in plasma specimens. J Clin Microbiol 1997, 35:2692-2694.
27. Blok MJ, Goossens VJ, Vanherle SJV, Top B, Tacken N, Middeldorp JM, et al.: Diagnostic value of monitoring CMV late pp67 mRNA expression in renal allograft recipients by nucleic-acid sequence-based amplification. J Clin Microbiol 1998, 36:1341-1346.
28. Imbert-Marcille BM, Robillard N, Poirier AS, Coste-Burel M, Cantarovich D. Milpied N, Billaudel S: Development of a method for direct quantification of cytomegalovirus antigenemia by flow cytometry. J Clin Microbiol 1997, 35:2665-2669.
29. Salzberger B, Myerson D, Boeckh M: Circulating CMV-infected endothelial cells in marrow transplant patients with CMV disease and CMV infection. J Infect Dis 1997, 176:778-781.
30. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M: Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood 1997, 90:2502-2508. Assessment of the risk factors, frequency, time patterns, and outcome of ganciclovir-related neutropenia until day 100 post transplant in a cohort of patients receiving ganciclovir at engraftment.
31. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied NJ, Camara R, et al.: Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. Bone Marrow Transplant 1997, 19:129-133.
32. Griffiths PD, Feinberg JE, Fry J, Sabin C, Dix L, Gor D, et al.: The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. J Infect Dis 1998, 177:57-64.
33. Bacigalupo A, Bregante S, Tedone E, Isaza A, VanLint MT, Trespi G, et al.: Combined foscamet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Bone Marrow Transplant 1996, 62:376-380.
34. Ippoliti C, Morgan A, Warkentin D, van Besien K, Mehra R, Khouri I, et al.: Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant 1997, 20:491-495.
35. Neyts J, Andrei G, de Clercq E: The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998, 42:216-222. Demonstrates mycophenolate mofetil to be a potent enhancer of the acyclic purine nucleoside analogues acyclovir, ganciclovir, and penciclovir.
36. Jabs DA, Enger C, Dunn JP, Forman M: for the CMV Retinitis and Viral Resistance Study Group: Cytomegalovirus retinitis and viral resistance: Ganciclovir resistance. J Infect Dis 1998, 177:770-773.
37. Erice A, Gil-Roda C, Perez JL, Balfour HH, Sannerud KJ, Hanson MN, et al.: Antiviral susceptibility and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997, 175:1087-1092.
38. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA: High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997, 176:69-77.
39. Tenney DJ, Yamanaka G, Voss SM, Cianci CW, Tuomari AV, Sheaffer AK, et al.: Lobucavir is phosphorylated in human cytomegalovirus-infected and-uninfected cells and inhibits the viral DNA polymerase. Antimicrob Agents Chemother 1997, 41:2680-2685.
40. De Cian W: Cidofovir, a new addition to the available therapies against cytomegalovirus. Monogr. Monogr. Virol 1998, 21:215-228.
41. Hamilton AA, Manuel DM, Grundy JE, Turner AJ, King SI, Adair JR, et al.: A humanized antibody against human cytomegalovirus gpUL75 (gH) for prophylaxis or treatment of CMV infections. J Infect Dis 1997, 176:59-68.